Literature DB >> 23681797

Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis.

Weixin Zhao1, Jianfeng Luo, Xuwei Cai.   

Abstract

Microsomal epoxide hydrolase 1 (EPHX1) plays an important role in the detoxification of carcinogenic polycyclic aromatic hydrocarbons. EPHX1 Tyr113His and His139Arg polymorphisms have been reported to have some impacts on the EPHX1 activity. Previous case-control studies assessing the associations between EPHX1 polymorphisms and esophageal cancer risk reported conflicting results. To quantitatively summarize the associations of EPHX1 Tyr113His and His139Arg polymorphisms with esophageal cancer risk, a systemic review and meta-analysis of published studies were performed. Published literatures from PubMed, Embase, and China National Knowledge Infrastructure databases were searched. The strength of the associations between EPHX1 polymorphisms and esophageal cancer risk was estimated by the pooled odds ratios (ORs) with its 95 % confidence interval (95 %CI). This meta-analysis yielded nine case-control studies, which included nine studies for Tyr113His polymorphism (1,291 cases and 2,120 controls) and seven studies for His139Arg polymorphism (899 cases and 1,615 controls). Overall, meta-analysis showed that EPHX1 Tyr113His polymorphism was not associated with esophageal cancer risk under all genetic models. Meta-analysis of these seven studies for EPHX1 His139Arg polymorphism showed that EPHX1 His139Arg polymorphism was also not associated with esophageal cancer risk under all genetic models. However, subgroup analysis by ethnicity further showed that there was an obvious association between EPHX1 His139Arg polymorphism and decreased risk of esophageal cancer in Caucasians (ArgArg versus HisArg/HisHis: OR = 0.52, 95 %CI 0.27-0.97, P = 0.041). This meta-analysis suggests that EPHX1 His139Arg polymorphism is associated with decreased risk of esophageal cancer in Caucasians. In addition, more studies with large samples are needed to get a more precise estimation on the associations mentioned above.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681797     DOI: 10.1007/s13277-013-0787-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

Review 1.  Epidemiology of esophageal cancer.

Authors:  Jason B Wheeler; Carolyn E Reed
Journal:  Surg Clin North Am       Date:  2012-08-20       Impact factor: 2.741

2.  A functional germline variant in the P53 polyadenylation signal and risk of esophageal squamous cell carcinoma.

Authors:  Liqing Zhou; Qipeng Yuan; Ming Yang
Journal:  Gene       Date:  2012-07-16       Impact factor: 3.688

3.  Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma.

Authors:  A G Casson; Z Zheng; D Chiasson; K MacDonald; D C Riddell; J R Guernsey; D L Guernsey; J McLaughlin
Journal:  Cancer Detect Prev       Date:  2003

4.  Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma.

Authors:  Alan G Casson; Zuoyu Zheng; Geoffrey A Porter; Duane L Guernsey
Journal:  Cancer Detect Prev       Date:  2006-10-24

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Interactions between Glutathione-S-Transferase M1, T1 and P1 polymorphisms and smoking, and increased susceptibility to esophageal squamous cell carcinoma.

Authors:  Omeed Moaven; Hamid Reza Raziee; Hamid Reza Sima; Azita Ganji; Reza Malekzadeh; Azadeh A'rabi; Abbas Abdollahi; Bahram Memar; Masoud Sotoudeh; Hossein Naseh; Navid Nekoui; Adeleh Razavipour; Mehran Gholamin; Ezzat Dadkhah; Moein Farshchian; Mohammad Reza Abbaszadegan
Journal:  Cancer Epidemiol       Date:  2010-04-20       Impact factor: 2.984

7.  Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage.

Authors:  Qian Wang; Wei Pang; Zhuan Cui; Junbao Shi; Yan Liu; Bo Liu; Yunfeng Zhou; Youfei Guan; Bruce D Hammock; Yue Wang; Yi Zhu
Journal:  Am J Physiol Renal Physiol       Date:  2012-11-14

8.  CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: study of population from a high- incidence area in north China.

Authors:  Li-Dong Wang; Shu Zheng; Bin Liu; Jian-Xiang Zhou; Yan-Jie Li; Ji-Xue Li
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 9.  The telltale structures of epoxide hydrolases.

Authors:  Michael Arand; Annette Cronin; Franz Oesch; Sherry L Mowbray; T Alwyn Jones
Journal:  Drug Metab Rev       Date:  2003-11       Impact factor: 4.518

Review 10.  Systematic review and meta-analysis of the relationship between EPHX1 polymorphisms and colorectal cancer risk.

Authors:  Fei Liu; Ding Yuan; Yonggang Wei; Wentao Wang; Lvnan Yan; Tianfu Wen; Mingqing Xu; Jiayin Yang; Bo Li
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

View more
  4 in total

1.  The association between the Arg280His polymorphism in the XRCC1 gene and the risk of hematological malignancies.

Authors:  Xiang Tong; Jiqiao Yang; Yuanling Peng; Jiani Shen; Tianyuan Xiong; Yonggang Zhang; Hong Fan
Journal:  Tumour Biol       Date:  2013-10-06

2.  Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis.

Authors:  Hong-Qiang Liu; Chang-Po Zhang; Chang-Zhen Zhang; Xiang-Chen Liu; Zun-Jing Liu
Journal:  Biomed Res Int       Date:  2015-01-06       Impact factor: 3.411

3.  Quantitative assessment of the influence of EPHX1 gene polymorphisms and cancer risk: a meta-analysis with 94,213 subjects.

Authors:  Xiaoqin Yang; Yubing Wang; Guiping Wang
Journal:  J Exp Clin Cancer Res       Date:  2014-09-28

Review 4.  Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta-analysis and genome-wide association studies.

Authors:  Jie Tian; Caiyang Liu; Guanchu Liu; Chunjian Zuo; Huanwen Chen
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.